Bladder cancer: Realities and perspectives;Actualités dans les cancers de la vessie

Bulletin du Cancer

Volumn 90, Issue 1, 2003, Pages 61-67

  Chrétien, Yves ^a   Oudard, Stéphane ^b   Durdux, Catherine ^b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b Hop Eur Georges Pompidou ^*  (France)

Author keywords

Bladder; Chemotheray; Radiation therapy; Surgery; Urothelial cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; PACLITAXEL; TRASTUZUMAB; VINBLASTINE;

ANEMIA; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CYSTECTOMY; DIARRHEA; FEBRILE NEUTROPENIA; HEMATOLOGIC DISEASE; HUMAN; METASTASIS; MUCOSA INFLAMMATION; NEUTROPENIA; PLASTIC SURGERY; QUALITY OF LIFE; REVIEW; SUPERFICIAL CANCER; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT OUTCOME; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; CYSTECTOMY; DOXORUBICIN; FEMALE; GENES, ERBB-2; HUMANS; MALE; METHOTREXATE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RADIOTHERAPY DOSAGE; URINARY BLADDER NEOPLASMS; VINBLASTINE;

EID: 0037283057     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Pfister C. New trends for optimal management of bladder tumors. J Urol 2001; 165: 65-6.
2. Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani P, Fair W. The treated natural history of hight risk superficial bladder cancer: 15-year outcome. J Urol 1997; 158: 62-7.
3. Herr HW. Tumour progression and survival in patients with T1G3 bladder tumours :15 years outcome. Br J Urol 1997; 80: 162-5.
4. Tolley DA, Parmar MKB, Gtigor KM, Lallemand G, Benyon LL, Fellows J, et al. The effect of intra-vesical mitomycin on recurrence of newly diagnosed supeficial bladder cancer: a further report with 7 years of follow-up. J Urol 1996; 155: 1233-8.
5. Oosterlinck W, Kurth KH, Shroeder F, Bultinck J, Hammond B, Sylvester R and menbers of the European Organisation for Research and Treatement of Cancer Genitourinary Group. A prospective European Organisation for Research and treatement of Cancer genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 1993; 142: 749-52.
6. Oosterlinck W, Lobel B, Jackse G, Malmstrom PU, Stockle M, Sternberg C. The EAU Working Group on Oncological Urology: guidelines on bladder cancer. Eur Urol 2002; 41: 105-12.
7. Housset M, Maulard C, Chrétien Y. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol 1993; 11: 2150-7.
8. Amling CL, Thrascher JB, Frazier HA: Radical cystectomy for stages TA, TIS and T1 transitional cell carcinoma of the bladder. J Urol 1993; 151: 31-6.
9. Malkowicz SB, Nichols P, Lieskovsky G. The role of tadical cystectomy in the management of high grade superficial bladder cancer (PA, P1, PIS, and P2). J Urol 1990; 144: 641-5.
10. Leissner J, Hohenfellner R, Thüroff JW, Wolf HK. Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder, significance for staging and prognosis. Br J Urol 2000; 85: 817-23.
11. Lebret T, Herve JM, Yonneau L, Molinie V, et al. Congrès AUA Anaheim 2001.
12. Soulie M, De Petriconi R, Gschwend J, Hautmann R, Gnann R. La nouvelle technique d'anastomose utétéro-iléale dans la néovessie iléale de Hautmann. Prog Urol 2001; 11: 29-33.
13. Pontvert D, Giraud P, Gaboriaud G. La radiothérapie dans le traitement des tumeurs infiltrantes de vessie. Oncol 2000, 2: 340-347.
14. Shelley MD, Barber J, Wilt T, Mason MD. Cochrane Database Syst Rev 2002; (1): CD002079
15. Naslund I, Nilsson B, Littbrand B. Hyperfractionated radiotherapy of bladder cancer: a ten-year follow-up of randomized trial. Acta Oncol 1994; 33: 397-402.
16. Feneley MR, Schoenberg M. Bladder-sparing strategies for transitional cell carcinoma. Urol 2000; 56: 549-60.
17. Miyanaga N, Akaza H, Okumura T, Sekido N, Kawai K, Shimazui T, et al. A bladder preservation regimen using intra-arterial chemotherapy and radiotherapy for invasive bladder cancer. Int J Urol 2000; 7: 41-8.
18. Ganaha F, Ymada T, Ujira M, Irie T, Fukuda Y, Fukuda K. Intra-arterial low-dose cisplatin via an indwelling port and concurrent radiotherapy for invasive bladder cancer. J Vasc Interv Radiol 2001; 12: 379-84.
19. Goonewardene TI, Bozcuk H, Oliver RT, Barua J, Nargund V, Philip T, et al. Phase 1/2 of synchronous methotrexate, cisplatine, vincristine chemotherapy and radiation for patients with locally advanced bladder cancer. Urol Int 2001; 67: 293-7.
20. Varveris H, Delakas D, Anezinis P, Haldeopoulos D, Mazonakis M, Damilakis J, et al. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma: a preliminary report of tolerance and local control. Anticancer Res 1997; 17: 4771-80.
21. Budgell G, Mott J, Logue J, Hounsell A. Clinical implementation of dynamic multileaf collimation for compensated bladder treatments. Radioth Oncol 2001; 59: 31-8.
22. Rodel C, Grabenbauer GG, Rodel F, Birkenhake S, Kuhn R, Martus P, et al. Apoptosis, p53, bcl2 and ki67 in invasive bladder carcinoma: possible predictors for response to radiochemotherapy and successful bladder preservation. Int J Radiat Oncol Biol Phys 2000; 46: 1213-21.
23. Pollack A, Wu CS, Cserniak B, Zagars GK, Benedict WF, Mc Donnel TJ. Abnormal bcl2 and pRB expression are independant correlates of radiation response in muscle-invasive bladder cancer. Clin Cancer Res 1997; 3: 1823-9.
24. Zietman AL, Grocela J, Zehr E, Kaufman DS, Young RH, Althausen AF, et al. Selective bladder conservation using transutethral resection, chemotherapy and radiation: management and consequence of Ta, T1 and Tis recurrence within the retained bladder. Urology 2001; 58: 380-5.
25. Wammack R, Wricke C, Hohenfellner R. Long-term results of ileocecal continent urinary diversion in patients treated with and without previous pelvic irradiation. J Urol 2002; 167: 2058-62.
26. von-der-Maase H. Current and future perspectives in advanced bladder cancer: is there a new standard? Sem Oncol 2002; 29: 3-14.
27. Sternberg CN, Mulder PHM, Schornagel JH, Theodore C, Fossa SD, van-Oosterom AT, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no 30924. J Clin Oncol 2001; 19: 2638-46.
28. von-der-Maase H, Hansen SW, Roberts JT, Doglioti L, Olivier T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 17: 3068-77.
29. Carles J, Nogue M. Gemcitabine/carboplatin in advanced urothelial cancer. Semin Oncol 2001; 28: 19-24.
30. Carles J, Nogue M, Domenech M, Perez C, Saigi E, Villadiego K, et al. Carboplatine-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function. Oncology 2000; 59: 24-7.
31. Meluch AA, Greco FA, Burris HA, O'Rourke TO, Ortega G, Steis RG, et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelium tract: a phase II trial of the Minnie Pearl Cancer resaerch Network. J Clin Oncol 2001; 19: 3018-24.
32. Sternberg C N, Calabro F, Pizzocaro G, Marini L, Schnetzer S, Sella A. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 2001; 92: 2993-8.
33. Bellmunt J, Guillem V, Paz-Ares L, Gonzales-Latriba JL, Carles J, Batiste-Alenton E, et al. Phase I/II study of paclitaxel, cisplatin and gemcitabine in advanced transitional-cell carcinoma of the urothelium. J Clin Oncol 2000; 18: 3247-55.
34. Hussain M, Vaishampayan U, Du W, Redman B, Simth DC. Combination paclitaxel, carboplatin and gemcitabine is active treatment for advanced urothelial cancer. J Clin Oncol 2001; 19: 2527-33.
35. Dodd PM, McCaffrey JA, Hilton S, Mazumdar M, Herr H, Kelly WK, et al. Phase I evaluation of sequential doxorubicin + gemcitabine then ifosfamide + paclitaxel + cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract. J Clin Oncol 2000; 18: 840-6.
36. Wester K, Sjöström A, de-la-Torre M, Carlsson J, Malmström P. HER-2-A possible target for therapy of metastatic of metastatic urinary bladder carcinoma. Acta Oncologica 2002; 41: 282-8.